Clostridium difficile infection and pseudomembranous colitis

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 17, Issue 3, 2003, Pages 475-493

  Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antibiotics; Clostridium difficile; Colitis; Diarrhoea; Hospital acquired

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; FUSIDIC ACID; GATIFLOXACIN; MACROLIDE; METRONIDAZOLE; MEZLOCILLIN; MOXIFLOXACIN; NEOMYCIN; NITROFURANTOIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TICARCILLIN; TRIMETHOPRIM; UNINDEXED DRUG; UREIDOPENICILLIN DERIVATIVE; VANCOMYCIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL VACCINE; CEPHALOSPORIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GTI 160 246; IMMUNOGLOBULIN; PENICILLIN G; POLYMER; PROBIOTIC AGENT; TETRACYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; INTESTINE FLORA; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PSEUDOMEMBRANOUS COLITIS; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STRAIN DIFFERENCE; CRITICAL ILLNESS; PATHOGENICITY; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; COLON PERFORATION; CYTOTOXICITY TEST; DISEASE PREDISPOSITION; ELECTROLYTE DISTURBANCE; ENTEROCOCCUS FAECIUM; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HYPOALBUMINEMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION RISK; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; PARALYTIC ILEUS; SACCHAROMYCES BOULARDII; SEPTIC SHOCK; SIGMOIDOSCOPY; TOXIC MEGACOLON;

CLOSTRIDIUM DIFFICILE; CRITICAL ILLNESS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 0141575683     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6918(03)00017-9     Document Type: Review

References (129)

1. al Saif N. Brazier J.S. The distribution of Clostridium difficile in the environment of South Wales Journal of Medical Microbiology 45 1996 133-137
2. Viscidi R. Willey S. Bartlett J.G. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations Gastroenterology 81 1981 5-9
3. Wanahita A. Goldsmith E.A. Musher D.M. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile Clinical Infectious Diseases 34 2002 1585-1592
4. Wood M. When stool cultures from adult inpatients are appropriate Lancet 357 2001 901
5. Brazier J.S. The diagnosis of Clostridium difficile-associated disease Journal of Antimicrobial Chemotherapy 41 supplement C 1998 29-40
6. Barbut F. Lalande V. Daprey G. et al. Usefulness of simultaneous toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated disease European Journal of Clinical Microbiology and Infectious Diseases 19 2000 481-484
7. Landry M.L. Topal J. Ferguson D. et al. Evaluation of Biosite Triage Clostridium difficile panel for rapid detection of Clostridium difficile in stool samples Journal of Clinical Microbiology 39 2001 1855-1858
8. ® C. difficile panel, EIA for Tox A/B and cytotoxin assays Diagnostic Microbiology and Infectious Diseases 43 2002 257-263
9. Fekety R. Antibiotic-associated colitis In Mandell G.L. Douglas R.G. Bennett J.E. (eds) Principles and Practice of Infectious Diseases 4th edn 1994 978-987 Churchill Livingstone Edinburgh
10. Bartlett J.G. Treatment of antibiotic-associated pseudomembranous colitis Review of Infections Diseases 6 supplement 1 1984 S235-S241
11. Fekety R. Silva J. Buggy B. Deery H.G. Treatment of antibiotic associated colitis with vancomycin Journal of Antimicrobial Chemotherapy 14 supplement D 1984 97-102
12. Wilcox M.H. Spencer R.C. Clostridium difficile infection: responses, relapses and re-infections Journal of Hospital Infection 22 1992 85-92
13. Fekety R. McFarland L.V. Surawicz C.M. et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial Clinical Infectious Diseases 24 1997 324-333
14. Communicable Disease Surveillance Centre Clostridium difficile in England and Wales: 1999 Communicable Disease Reports CDR Weekly 10 2000 135
15. Communicable Disease Surveillance Centre Trends in selected gastrointestinal infections-2001 Communicable Disease Reports CDR Weekly 2002 http://www.phls.co.uk/publications/cdr/archive02/News/ news0702.html#GI2001 (accessed 17 December, 2002)
16. Kyne L. Merry C. O'Connell B. et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile Age & Ageing 28 1999 107-113
17. Bliss D.Z. Johnson S. Savik K. et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhoea in hospitalised patient receiving tube feeding Annals of Internal Medicine 129 1998 1012-1019
18. Wilcox M.H. Cunnliffe J.G. Trundle C. Redpath C. Financial burden of hospital-acquired Clostridium difficile infection Journal of Hospital Infection 34 1996 23-30
19. Kyne L. Hamel M.B. Polavaram R. Kelly C.P. Health care costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile Clinical Infectious Diseases 34 2002 346-353
20. Brazier J.S. The epidemiology and typing of Clostridium difficile Journal of Antimicrobial Chemotherapy 41 supplement C 1998 47-57
21. Dallal R.M. Harbrecht B.G. Boujoukas A.J. et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications Annals of Surgery 235 2002 363-372
22. Karlstrom O. Fryklund B. Tullus K. Burman L.G. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group Clinical Infectious Diseases 26 1998 141-145
23. Kyne L. Merry C. O'Connell B. et al. Community-acquired Clostridium difficile infection Journal of Infection 36 1998 287-288
24. Kyne L. Warny M. Qamar A. Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A New England Journal of Medicine 342 2000 390-397
25. Wilcox M.H. Smyth E.T. Incidence and impact of Clostridium difficile infection in the UK, 1993-1996 Journal of Hospital Infection 39 1998 181-187
26. Stubbs S.L. Brazier J.S. O'Neill G.L. Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes Journal of Clinical Microbiology 37 1999 461-463
27. Brazier J.S. Typing of Clostridium difficile Clinical Microbiology and Infection 7 2001 428-431
28. Kato H. Kato N. Watanabe K. et al. Analysis of Clostridium difficile isolates from nosocomial outbreaks at three hospitals in diverse areas of Japan Journal of Clinical Microbiology 39 2001 1391-1395
29. Cartmill T.D.I. Panigrahi H. Worsley M.A. et al. Management and control of a large outbreak of diarrhoea due to Clostridium difficile Journal of Hospital Infection 27 1994 1-15
30. Johnson S. Samore M.H. Farrow K.A. et al. Epidemics of diarrhoea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals New England Journal of Medicine 341 1999 1645-1651
31. Mulligan M.E. Rolfe R.D. Finegold S.M. George W.L. Contamination of a hospital environment by Clostridium difficile Current Microbiology 3 1979 173-175
32. Fekety R. Kim K.H. Batts D.H. et al. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment American Journal of Medicine 70 1981 906-908
33. Bender B.S. Laughton B.E. Gaydos C. et al. Is Clostridium difficile endemic in chronic care facilities? Lancet ii 1986 11-13
34. Fawley W.N. Wilcox M.H. Molecular typing of endemic Clostridium difficile infection Epidemiology & Infection 126 2001 343-350
35. Samore M.H. Venkataraman L. DeGirolami P.C. et al. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhoea American Journal of Medicine 100 1996 32-40
36. Verity P. Wilcox M.H. Fawley W. Parnell P. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms Journal of Hospital Infection 49 2001 204-209
37. Wilcox M.H. Fawley W.N. Wigglesworth N. et al. Comparison of effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection Journal of Hospital Infection 2003 in press
38. Perry C. Marshall R. Jones E. Bacterial contamination of uniforms Journal of Hospital Infection 48 2001 238-241
39. Manian F.A. Meyer L. Jenne J. Clostridium difficile contamination of blood pressure cuffs: a call for a closer look at gloving practices in the era of universal precautions Infection Control & Hospital Epidemiology 17 1996 180-182
40. Brooks S. Khan A. Stoica D. et al. Reduction in vancomycin-resistant enterococcus and Clostridium difficile infections following a change to tympanic thermometers Infection Control & Hospital Epidemiology 19 1998 333-336
41. Jernigan J.A. Siegman-Igra Y. Guerrant R.C. Farr B.M. A randomised crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections Infection Control & Hospital Epidemiology 19 1998 494-499
42. Borriello S.P. Barclay F.E. An in-vitro model of colonization resistance to Clostridium difficile infection Journal of Medical Microbiology 21 1986 299-309
43. Borriello S.P. Pathogenesis of Clostridium difficile infection Journal of Antimicrobial Chemotherapy 41 supplement C 1998 13-19
44. Yamazawa K. Kanno H. Seki K. et al. Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy Acta Obstetrica et Gynaecologica Scandinavica 80 2001 768-769
45. Gorschluter M. Glasmacher A. Hahn C. et al. Clostridium difficile infection in patients with neutropenia Clinical Infectious Diseases 33 2001 786-791
46. Aronsson B. Möllby R. Nord C.-E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982 Journal of Infectious Diseases 151 1985 476-481
47. Golledge C.L. McKenzie T. Riley T.V. Extended spectrum cephalosporins and Clostridium difficile Journal of Antimicrobial Chemotherapy 23 1989 929-931
48. de Lalla F. Privitera G. Ortisi G. et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital Journal of Antimicrobial Chemotherapy 23 1989 623-631
49. Wistrom J. Norrby S.R. Myhre E.B. et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study Journal of Antimicrobial Chemotherapy 47 2001 43-50
50. Ozawa T.T. Valadez T. Clostridium difficile infection associated with levofloxacin treatment Tennessee Medicine 95 2002 113-115
51. Yip C. Loeb M. Salama S. et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea Infection Control and Hospital Epidemiology 22 2001 572-575
52. Privetera G. Scarpellini P. Ortisi G. et al. Prospective study of Clostridium difficile intestinal colonization and disease following single dose antibiotic prophylaxis in surgery Antimicrobial Agents and Chemotherapy 35 1991 208-210
53. Anand A. Bashey B. Mir T. Glatt A.E. Epidemiology, clinical manifestations and outcome of Clostridium difficile-associated diarrhoea American Journal of Gastroenterology 89 1994 519-523
54. Settle C.D. Wilcox M.H. Fawley W.N. et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam Alimentary Pharmacology & Therapeutics 12 1998 1217-1223
55. Wilcox M.H. Brown A. Freeman J. Faecal concentrations of piperacillin and tazobactam in elderly patients Journal of Antimicrobial Chemotherapy 48 2001 155-156
56. Ambrose N.S. Johnson M. Burdon D.W. Keighley M.R.B. The influence of single dose intravenous antibiotics on faecal flora and emergence of Clostridium difficile Journal of Antimicrobial Chemotherapy 15 1985 319-326
57. Kreisel D, Savel TC, Silver AL & Cunningham JD. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity. Archives of Surgery 1995; 130: 989-993.
58. Borriello S.P. Barclay F.E. Welch A.R. et al. Epidemiology of diarrhoea caused by enterotoxigenic Clostridium perfringens Journal of Medical Microbiology 20 1985 363-372
59. Hancock P. Antibiotic-associated diarrhoea: C. difficile or C. perfringens? Reviews in Medical Microbiology 8 supplement 1 1997 S66-S67
60. Modi N. Wilcox M.H. Evidence for antibiotic induced Clostridium perfringens diarrhoea Journal of Clinical Pathology 54 2001 748-751
61. Asha N. Wilcox M.H. Laboratory diagnosis of Clostridium perfringens antibiotic associated diarrhoea Journal of Medical Microbiology 51 2002 891-894
62. Collie R.E. McClane B.A. Evidence that the enterotoxin gene can be episomal in Clostridium perfringens isolates associated with non-food-borne human gastrointestinal diseases Journal of Clinical Microbiology 36 1998 30-36
63. Gravet A. Rondeau M. Harf-Monteil C. et al. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD Journal of Clinical Microbiology 37 1999 4012-4019
64. Nusrat A. von Eichel-Streiber C. Turner J.R. et al. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins Infection & Immunity 69 2001 1329-1336
65. Cohen S.H. Tang Y.J. Silva J.J Analysis of the pathogenicity locus in Clostridium difficile strains Journal of Infectious Diseases 181 2000 659-663
66. Kato H. Kato N. Watanabe K. et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR Journal of Clinical Microbiology 36 1998 2178-2182
67. Embil J. Al-Barrak A. Dyek B. et al. The one year experience following an outbreak of toxin A (-) toxin B (+) Clostridium difficile associated disease in an Canadian tertiary care hospital Clinical Infectious Diseases 29 1999 1041 abstract 451
68. Limaye A.P. Turgeon D.K. Cookson B.T. Fritsche T.R. Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile Journal of Clinical Microbiology 38 2000 1696-1697
69. Brazier J.S. Stubbs S.L. Duerden B.I. Prevalence of toxin A negative/B positive Clostridium difficile strains Journal of Hospital Infection 42 1999 248-249
70. Al-Barrak A. Embil J. Dyck B. et al. An outbreak of toxin A negative, toxin B positive Clostridium difficile-associated diarrhea in a Canadian tertiary-care hospital Canada Communicable Disease Report 25 1999 65-69
71. Sambol S. Gerding D. Merrigan M. et al. Severe truncation of the toxin A gene in a pathogenic Clostridium difficile (CD) strain not detectable by toxin A immunoassay Clinical Infectious Diseases 27 1998 946 abstract 139
72. Lyerly D.M. Neville L.M. Evans D.T. et al. Multicenter evaluation of the Clostridium difficile TOX A/B TEST Journal of Clinical Microbiology 36 1998 184-190
73. Johnson S. Kent S.A. O'Leary K.J. et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay Annals of Internal Medicine 135 2001 434-438
74. Viscidi R. Laughon B.E. Yolken R. et al. Serum antibody response to toxins A and B of Clostridium difficile Journal of Infectious Diseases 148 1983 93-100
75. Warny M. Vaerman J.P. Avesani V. Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection Infection & Immunity 62 1994 384-389
76. Shim J.K. Johnson S. Samore M.H. et al. Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhoea Lancet 351 1998 633-636
77. Kyne L. Warny M. Qamar A. Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile infection Lancet 357 2001 189-193
78. Starr J.M. Rogers T.R. Impallomeni M. Hospital-acquired Clostridium difficile diarrhoea and herd immunity Lancet 349 1997 426-428
79. Climo M.W. Israel D.S. Wong E.S. et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhoea and cost Annals of Internal Medicine 128 1998 989-995
80. Ludlam H. Brown N. Sule O. et al. An antibiotic policy associated with reduced risk of Clostridium difficile-associated diarrhoea Age & Ageing 28 1999 578-580
81. Pear S.M. Williamson T.H. Bettin K.M. et al. Decrease in nosocomial Clostridium difficile-associated diarrhoea by restricting clindamycin use Annals of Internal Medicine 120 1994 272-277
82. McNulty C. Logan M. Donald I.P. et al. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy Journal of Antimicrobial Chemotherapy 40 1997 707-711
83. Stone S. Kibbler C. How A. Balstrini A. Feedback is necessary in strategies to reduce hospital acquired infection British Medical Journal 321 2000 302-303
84. Johnson S. Gerding D.N. Olson M.M. et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission American Journal of Medicine 88 1990 137-140
85. Bettin K. Clabots C. Mathie P. et al. Effectiveness of liquid soap vs. chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands Infection Control & Hospital Epidemiology 15 1994 697-702
86. Lucet J.C. Rigaud M.P. Mentre F. et al. Hand contamination before and after different hand hygiene techniques: a randomised clinical trial Journal of Hospital Infection 50 2002 276-280
87. Mayfield J.L. Leet T. Miller J. Mundy L.M. Environmental control to reduce transmission of Clostridium difficile Clinical Infectious Diseases 31 2000 995-1000
88. Kaatz G.W. Gitlin S.D. Schaberg D.R. et al. Acquisition of Clostridium difficile from the hospital environment American Journal of Epidemiology 127 1988 1289-1293
89. Wilcox M.H. Fawley W.N. Hospital disinfectants and spore formation by Clostridium difficile Lancet 356 2000 1324
90. Teasley D.G. Gerding D.N. Olson M.M. et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis Lancet ii 1983 1043-1046
91. Wilcox M.H. Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin Journal of Antimicrobial Chemotherapy 36 1995 673-679
92. Pelaez T. Alcala L. Alonso R. et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin Antimicrobial Agents & Chemotherapy 46 2002 1647-1650
93. Brazier J.S. Fawley W.N. Freeman J. Wilcox M.H. Reduced susceptibility of Clostridium difficile to metronidazole Journal of Antimicrobial Chemotherapy 48 2001 741-742
94. O'Neill G.L. Beaman M.H. Riley T.V. Relapse versus reinfection with Clostridium difficile Epidemiology & Infection 107 1991 627-635
95. Wilcox M.H. Fawley W.N. Settle C.D. Davidson A. Recurrence of symptoms in Clostridium difficile infection-relapse or reinfection? Journal of Hospital Infection 38 1998 93-100
96. Tedesco F.J. Gordon D. Fortson W.C. Approach to patients with multiple relapses of antibiotic associated pseudomembranous colitis American Journal of Gastroenterology 80 1985 867-868
97. Taylor N.S. Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion exchange resins Journal of Infectious Diseases 141 1980 92-97
98. Adam J. Barret A. Barrett-Bellet C. et al. Essais cliniques controles en double insu de l'ultra-levure lyophilisee. Etude multicentrique par 25 medecins de 388 cas Gazette Medicale Francaise 84 1977 2072-2078
99. Surawicz C.M. Elmer G.M. Speelman P. et al. Prevention of antibiotic-association diarrhea by Saccharomyces boulardii: a prospective study Gastroenterology 96 1989 981-988
100. McFarland L.V. Surawicz C.M. Greenberg R.N. et al. Prevention of beta-lactam-associated diarrhoea by Saccharomyces boulardii compared with placebo American Journal of Gastroenterology 90 1995 439-448
101. Ligny G. Le traitement par l'ultra-levure des troubles intestinaux secondaires a l'antibiotherapie: etude en double aveugle et etude clinique simple Revue Francaise de Gastroenterologie 114 1975 45-50
102. McFarland L.V. Surawicz C.M. Greenberg R.N. et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease Journal of the American Medical Association 271 1994 1913-1918
103. Pothoulakis C. Kelly C.P. Joshi M.A. et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum Gastroenterology 104 1993 1108-1115
104. Fredenucci I. Chomarat M. Boucaud C. Flandrois J.P. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy Clinical Infectious Diseases 27 1998 222-223
105. Niault M. Thomas F. Prost J. et al. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii Clinical Infectious Diseases 28 1999 930
106. McCullough M.J. Clemons K.V. McCluster J.H. Stevens D.A. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.) Journal of Clinical Microbiology 36 1998 2613-2617
107. Beck C. Necheles H. Beneficial effects of the administration of Lactobacillus acidophilus in diarrheal and other intestinal disorders American Journal of Gastroenterology 35 1961 522-530
108. Settel E. Lactobacillus acidophilus in the treatment of functional gastrointestinal disorders Clinical Medicine 69 1962 700-704
109. Gotz V. Romankiewicz J.A. Moss J. Murray H.W. Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation American Journal of Hospital Pharmacy 36 1979 754-757
110. Gorbach S.I. Chang T.W. Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG Lancet ii 1987 1519
111. Siitonen S. Vapaatalo H. Salminen S. et al. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhea Annals of Medicine 22 1990 57-59
112. Lewenstein A. Frigerio G. Moroni M. Biological properties of SF 68. A new approach for the treatment of diarrheal diseases Current Therapeutic Research 26 1979 967-981
113. Seal D. Borriello S.P. Barclay F. et al. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain European Journal of Microbiology 6 1987 51-53
114. Schellenberg D. Bonington A. Champion C.M. et al. Treatment of Clostridium difficile diarrhoea with brewer's yeast Lancet 343 1994 171-172
115. Thomas M.R. Litin S.C. Osmon D.R. et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial Mayo Clinic Proceedings 76 2001 883-889
116. Bowden T.A. Mansberger A.L. Lykins L.E. Pseudomembranous enterocolitis: mechanism of restoring floral homeostasis American Surgeon 47 1981 178-183
117. Schwan A. Sjolin S. Trottestam U. Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces Scandinavian Journal of Infection Diseases 16 1984 211-215
118. Tvede M. Rask-Madend J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients Lancet i 1989 1156-1160
119. Johnson S. Homann S.R. Bettin K.M. et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial Annals of Internal Medicine 117 1992 297-302
120. Gerding D.N. Olson M.M. Johnson S. Clostridium difficile diarrhea and colonization after treatment with abdominal infection regimens containing clindamycin or metronidazole American Journal of Surgery 159 1990 212-217
121. Cleary R.K. Grossman R. Fernandez F.B. et al. Metronidazole may inhibit intestinal colonization with Clostridium difficile Diseases of the Colon & Rectum 41 1998 464-467
122. Torres J.F. Lyerly D.M. Hill J.E. Monath T.P. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by perenteral and mucosal routes of immunization in hamsters Infection & Immunity 63 1995 4619-4627
123. Ryan E.T. Butterton J.R. Smith R.N. et al. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain Infection & Immunity 65 1997 2941-2949
124. Salcedo J. Keates S. Pothoulakis C. et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis Gut 41 1997 366-370
125. Lyerly D.M. Bostwick E.F. Binion S.B. Wilkins T.D. Passive immunisation of hamsters against disease caused by Clostridium difficile by use of a bovine immunoglobulin G concentrate Infection & Immunity 59 1991 2215-2218
126. Kelly C.P. Pothoulakis C. Vavva F. et al. Anti-C. difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins Antimicrobial Agents & Chemotherapy 40 1996 373-379
127. Kelly C.P. Chetham S. Keates S. et al. Survival of anti-C. difficile bovine immunoglobulin concentrate in the human gastrointestinal tract Antimicrobial Agents & Chemotherapy 41 1997 236-241
128. Kotloff K.L. Wasserman S.S. Losonsky G.A. et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults Infection & Immunity 69 2001 988-995
129. Kurtz C.B. Cannon E.P. Brezzani A. et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis Antimicrobial Agents & Chemotherapy 45 2001 2340